| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10020897 | HBV | ENSG00000165140.12 | protein_coding | FBP1 | No | No | 2203 | P09467 Q2TU34 |
| TVIS20000695 | HPV | ENSG00000165140.12 | protein_coding | FBP1 | No | No | 2203 | P09467 Q2TU34 |
| TVIS20040568 | HPV | ENSG00000165140.12 | protein_coding | FBP1 | No | No | 2203 | P09467 Q2TU34 |
| TVIS20031615 | HPV | ENSG00000165140.12 | protein_coding | FBP1 | No | No | 2203 | P09467 Q2TU34 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | FBP1 |
|---|---|
| DrugBank ID | DB00131 |
| Drug Name | Adenosine phosphate |
| Target ID | BE0002431 |
| UniProt ID | P09467 |
| Regulation Type | antagonist |
| PubMed IDs | 7809062; 18650089 |
| Citations | Xue Y, Huang S, Liang JY, Zhang Y, Lipscomb WN: Crystal structure of fructose-1,6-bisphosphatase complexed with fructose 2,6-bisphosphate, AMP, and Zn2+ at 2.0-A resolution: aspects of synergism between inhibitors. Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):12482-6.@@Hebeisen P, Kuhn B, Kohler P, Gubler M, Huber W, Kitas E, Schott B, Benz J, Joseph C, Ruf A: Allosteric FBPase inhibitors gain 10(5) times in potency when simultaneously binding two neighboring AMP sites. Bioorg Med Chem Lett. 2008 Aug 15;18(16):4708-12. doi: 10.1016/j.bmcl.2008.06.103. Epub 2008 Jul 5. |
| Groups | Approved; Investigational; Nutraceutical; Withdrawn |
| Direct Classification | Purine ribonucleoside monophosphates |
| SMILES | NC1=C2N=CN([C@@H]3O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]3O)C2=NC=N1 |
| Pathways | Leigh Syndrome; Histidinemia; Guanidinoacetate Methyltransferase Deficiency (GAMT Deficiency); Fatty Acid Metabolism; Gentamicin Action Pathway; Pyruvate Dehydrogenase Complex Deficiency; Purine Nucleoside Phosphorylase Deficiency; Hyperprolinemia Type II; Glutamate Metabolism; Clarithromycin Action Pathway; Argininosuccinic Aciduria; Pyruvate Decarboxylase E1 Component Deficiency (PDHE1 Deficiency); Hyperinsulinism-Hyperammonemia Syndrome; Butyrate Metabolism; Pyruvate Metabolism; Pentose Phosphate Pathway; Propanoate Metabolism; Glycine and Serine Metabolism; Selenoamino Acid Metabolism; Thiamine Metabolism; Oxytetracycline Action Pathway; Tetracycline Action Pathway; Carbamoyl Phosphate Synthetase Deficiency; Hyperprolinemia Type I; Histidine Metabolism; Cystathionine beta-Synthase Deficiency; Arginine and Proline Metabolism; Roxithromycin Action Pathway; Purine Metabolism; Ammonia Recycling |
| PharmGKB | PA164744376 |
| ChEMBL | CHEMBL752 |
